Brief: Travere Therapeutics Announces Planned Chief Executive Officer Transition
21/09/2026 21:18
BRIEF-Travere Therapeutics Announces Planned Chief Executive Officer Transition Sept 22 (Reuters) - Travere Therapeutics, Inc. TVTX.O:
TRAVERE THERAPEUTICS ANNOUNCES PLANNED CHIEF EXECUTIVE OFFICER TRANSITION
TRAVERE THERAPEUTICS, - APPOINTS BRADLEY L. CAMPBELL AS PRESIDENT AND CEO EFFECTIVE DECEMBER 1, 2026
TRAVERE THERAPEUTICS, - ERIC DUBE TO STEP DOWN AS PRESIDENT AND CEO IN DECEMBER
Source text: ID:nBw5nJfCqa
Further company coverage: TVTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Travere Therapeutics
See all newsBrief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Travere Therapeutics - Receives USPTO Notice Of Allowance For Filspari Patent In FSGS
Brief: Travere Therapeutics Announces Planned Chief Executive Officer Transition
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule